TNDM - Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. TNDM is well-poised to grow in the coming quarters as the rising prevalence of diabetes and increasing adoption of connected care continue to support demand for automated insulin delivery. The company's pay-as-you-go reimbursement model could lower upfront barriers for pump starts and support higher supply revenue per customer over time.
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--The t:slim X2™ insulin pump from Tandem Diabetes Care is now compatible with Abbott's FreeStyle Libre 3 Plus CGM sensor in five EU countries.
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2026 results after th
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2026 results after the financial markets close on Thursday, August 6, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2026 financial and operating results.A live webcast of the call will be available on Tandem Diabet.
Tandem Diabetes Care, Inc. (TNDM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
The average of price targets set by Wall Street analysts indicates a potential upside of 56.2% in Tandem Diabetes Care (TNDM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced receipt of CE mark for expanded indicati
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #TandemMobi--Tandem Diabetes Care receives CE mark for AID systems in Europe to include use in type 1 diabetes during pregnancy and adults with type 2 diabetes.
TNDM's pay-as-you-go shift, international expansion and strong liquidity support growth, while macro and reimbursement risks remain.
Broker upgrades flag upside in Tandem, Dell and CNO Financial as earnings forecasts jump and analysts lift ratings over the past four weeks.
TNDM trades near 1.1x forward sales as it shifts to pharmacy pay-as-you-go and expands Europe, with a $21 target tied to 1.3x sales.
Tandem Diabetes' Q1 beat, fatter margins and positive cash flow fuel its 2026 reset as it shifts more U.S. pump starts to pay-as-you-go pharmacy.
On May 28, 2026, Tandem Diabetes Care Inc (TNDM) shares experienced a notable rise of 12.9%, bringing the current price to $16.74. The stock has fluctuated with
Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.
Tandem Diabetes beats Q1 revenue and earnings estimates as gross margin expands, but shares decline 23.6% after the results announcement.
Tandem Diabetes Care, Inc. (TNDM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Tandem Diabetes Care (TNDM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Tandem Diabetes Care, Inc. (TNDM) Q1 2026 Earnings Call Transcript
Tandem Diabetes Care NASDAQ: TNDM reported record first-quarter pump shipments and sales for 2026, while reaffirming its full-year outlook as the diabetes technology company advances a shift toward pharmacy-channel reimbursement, expands direct international operations and prepares several product launches.
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $0.67 per share a year ago.